- Home
- CR vs AXSM Comparison
CR vs AXSM Comparison
Compare CR & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CR | AXSM |
|---|---|---|
| Founded | 1855 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.0B |
| IPO Year | 2022 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CR | AXSM |
|---|---|---|
| Price | $182.36 | $232.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $226.20 | $211.12 |
| AVG Volume (30 Days) | 468.9K | ★ 812.7K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | 23.96 | ★ 38.56 |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $2,305,000,000.00 | N/A |
| Revenue This Year | $27.98 | $57.24 |
| Revenue Next Year | $5.76 | $55.88 |
| P/E Ratio | $158.97 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $159.58 | $96.09 |
| 52 Week High | $214.31 | $238.56 |
Technical Indicators
Market Signals| Indicator | CR | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 68.84 |
| Support Level | $175.80 | $179.00 |
| Resistance Level | $184.91 | $235.10 |
| Average True Range (ATR) | 5.61 | 6.77 |
| MACD | 0.88 | -1.06 |
| Stochastic Oscillator | 83.52 | 80.17 |
Price Performance
Historical ComparisonAbout CR Crane Company
Crane is a diversified industrial firm that manufactures a broad range of products, including valves, pumps, aerospace components, and fiberglass-reinforced plastic panels. Its business is organized into two segments: aerospace and advanced technologies, and process flow technologies. Crane generated approximately $2.3 billion in revenue in 2025.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.